Trial Profile
Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Abatacept (Primary)
- Indications Granulomatosis with polyangiitis
- Focus Therapeutic Use
- Acronyms ABROGATE
- 03 Feb 2023 Status changed from recruiting to active, no longer recruiting.
- 02 May 2022 Planned primary completion date changed from 1 Aug 2023 to 1 Sep 2023.
- 30 Apr 2019 Planned number of patients changed from 150 to 66.